Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease characterized by progressive scarring of lung ...

Researchers assessed the effect of long-term air pollution exposure on disease severity and progression in patients with idiopathic pulmonary fibrosis.

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

The following is a summary of “Progressive Early Interstitial Lung Abnormalities in Persons at Risk for Familial Pulmonary ...

Pandey: Pulmonary fibrosis is a term used when there is a progression of fibrosis in the lungs. It is a diffuse lung disease. Lung is an elastic organ. During pulmonary fibrosis, the lung function ...

said anti-fibrotic medicines and oxygen can delay the progression of the disease, prolonging life by seven-eight years. "There is no cure for idiopathic pulmonary fibrosis. Lung transplant ...

Pulmonary fibrosis is an interstitial lung disease ... Doctors will also monitor the progression of the disease with lung function tests, carbon monoxide diffusion testing and six-minute walk ...

Conventional drug development typically zeroes in on individual proteins or signaling pathways. By focusing on the ...